TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

Transcenta, biologics, antibody

TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

contact
背景
Target:
BMP Antagonist (FIC)
Indication:
Prostate cancer, NSCLC, CRC, ESCC, GC, PADC, Breast Cancer etc
Project Status:
Phase I

TST003 is a high affinity monoclonal antibody targeting Gremlin1, a member of TGFb superfamily. Gremlin1 protein is a highly conserved secreted protein and has shown to play important roles during development.  Gremlin1 is highly upregulated in multiple solid tumors. Gremlin1 protein promotes epithelial mesenchymal transition. TST003 has shown promising single agent activities in patient-derived xenograft tumor models of multiple difficult-to-treat solid tumors resistant to checkpoint inhibitor including castration resistant prostate cancer and microsatellite stable colorectal cancer. TST003 also enhanced the anti-tumor activity of checkpoint inhibitor in syngeneic tumor model. TST003 has received FDA clearance for entering clinical testing in September, 2022.

Mechanism of Action

•       Novel BMP antagonist

•       Target highly expressed in stromal cells in tumor microenvironment

•       Targeting CPI resistant/ineligible solid tumors including Prostate cancer, NSCLC, CRC, ESCC, GC, PADC, Breast Cancer et

2022 Post-TEMTIA Business Update_TST003_1109_eng_squeezedv1.jpg


Collabarations

Academic Collaboration

Researchers from Transcenta and Shanghai Jiao Tong University investigated the therapeutic potential of anti-Gremlin1 for prostate cancer in an aggressive mouse model of CRPC (Pbsn-Cre4; Ptenfl/fl; Trp53fl/fl GEMM) and patient derived xenograft (PDX), using TST003, a humanized Gremlin1-targeting antibody, and a surrogate antibody generated by Transcenta.

交大.png

TOP